Article
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Dec 2022
Grote Isabel, Bartels Stephan, Christgen Henriette, Radner Martin, Gronewold Malte, Kandt Leonie, Raap Mieke, Lehmann Ulrich, Gluz Oleg, Graeser Monika, Kuemmel Sherko, Nitz Ulrike, Harbeck Nadia, Kreipe Hans, Christgen Matthias
Abstract excerpt
Invasive lobular breast cancer (ILC) is a special breast cancer (BC) subtype and is mostly hormone receptor (HR)-positive and ERBB2 non-amplified. Endocrine therapy restrains tumor proliferation and is the mainstay of lobular BC treatment. Mutation of ERBB2 has been associated with recurrent ILC. However, it is unknown whether ERBB2 mutation impacts on the otherwise exquisite responsiveness of early ILC to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.